59 results
6-K
EX-99.1
GNFT
Genfit
25 Apr 24
Current report (foreign)
4:10pm
of engaging policies and the tracking of performance indicators aligned with our key issues. The implementation of our CSR strategy is a priority
6-K
EX-99.1
GNFT
Genfit
7 Dec 23
Ipsen confirms U.S. FDA grants priority review for New Drug Application for elafibranor for the treatment of rare cholestatic liver disease, PBC
6:37am
The forward-looking statements, objectives and targets contained herein are based on Ipsen’s management strategy, current views and assumptions
6-K
EX-99.1
GNFT
Genfit
6 Dec 23
Current report (foreign)
11:30am
Hospital in Paris, France, stated: “Most late-stage MASH trials do not have a well-defined, non-invasive strategy for referring patients to liver biopsy
6-K
EX-99.1
doqim1ff8
16 Nov 23
GENFIT Highlights ACLF Development Strategy at “ACLF Day” during AASLD The Liver Meeting® 2023
4:10pm
6-K
EX-99.1
aja4xu 8v4
13 Nov 23
Current report (foreign)
4:30pm
6-K
EX-99.1
nxy63p64wwn5egswu4
20 Sep 23
GENFIT Reports First Half-Year 2023 Financial Results and Provides Corporate Update
4:51pm
6-K
EX-99.1
9dn74u
20 Sep 23
Current report (foreign)
4:44pm
6-K
EX-99.1
4t6it ckyl4hf
30 Jun 23
Current report (foreign)
6:00am
6-K
EX-99.1
wiquax
31 May 23
GENFIT Further Strengthens its ACLF Franchise with a Third Clinical-Stage Asset
4:15pm
F-3
wnsbdlna328zywwd15i
18 Apr 23
Shelf registration (foreign)
2:33pm
6-K
EX-99.1
vrn4j2cdgto5 bevb3
17 Nov 22
GENFIT Pipeline Day Highlights Diverse Product Portfolio in Underserved Liver Diseases
4:10pm
6-K
EX-99.1
4cueear8si f23faw
28 Sep 22
GENFIT Reports First Half-Year 2022 Financial Results and Provides Corporate Update
4:13pm
6-K
EX-99.2
74v1zx
28 Sep 22
GENFIT Reports First Half-Year 2022 Financial Results and Provides Corporate Update
4:13pm
6-K
EX-99.1
ihzc33mtvglu avxs
19 Sep 22
GENFIT to Acquire Clinical-stage Biopharmaceutical Company Versantis, expanding its Portfolio in Liver Diseases
6:10am